Skip to main content
Susana de la Luna

Susana de la Luna

Centre de Regulació Genòmica

Life & Medical Sciences

I obtained a BsC in Biology in 1985 at Universidad Autónoma de Madrid. For my PhD studies, I joined Juan Ortín's lab at the CBMSO and worked on the biology of influenza virus, characterizing molecularly and functionally the viral polymerase. After getting the PhD in 1989 at UAM, I stayed in Ortín's lab at CNB until 1994 when I moved to London to the lab of Nick La Thangue at the National Institute for Medical Research. There, I worked on the G1/S transition in the mammalian cell cycle focusing in the transcription factor E2F, with fellowships from the HFSO (at NIMR) and EU-Marie Curie (at Glasgow University) Programs. In 1998, I returned to Spain with a reintegration contract to join the HSA21/Down syndrome Research group led by Xavier Estivill (IRO, Barcelona). In 2002, I joined ICREA and established my own research group working on the functional characterization of the family of kinases DYRK and their relationship with disease at the Centre for Genomic Regulation-CRG.

Research interests

Protein kinases are central to all cellular processes in eukaryotes, and often linked to disease when they are altered. My group works on a family of protein kinases known as DYRK (dual-specificity tyrosine-regulated kinases), whose members -DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4- participate in the regulation of processes critical for cell viability and homeostasis. In general, alterations in DYRKs (expression or mutation) are linked to different cancer types. In addition, mutations in several DYRK genes are associated to developmental disorders, as in the case of the DYRK1A haploinsufficiency syndrome or the DYRK1B-associated metabolic syndrome. My group aims to dissect how DYRK activities are linked to human pathology. We are particularly interested on the DYRK-associated activities that impact on the regulation of expression programs either directly on chromatin or indirectly through modulation of signaling pathways.

Selected research activities

Funded Projects:

* 2020-2023 DYRK1A inhibition to remodel tumor stroma and sensitize immune checkpoint blockade therapies in pancreatic cancer (Fundació La Marató de TV3).

* 2020-2023 DYRK1A protein kinase as a regulator of transcription and intracellular signaling (MICINN).

* 2020-2022 Organization of the DYRK1A interactome through docking domains: searching for novel targeting approaches (Fondation Jerome LEJEUNE).


* Three PhD Thesis on-going.

* One Master Thesis on-going.

ICREA Memoir 2021